Drug Landscape ›
Gabapentin 300mg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 159
Most-reported reactions
Dyspnoea — 22 reports (13.84%) Dizziness — 21 reports (13.21%) Confusional State — 16 reports (10.06%) Drug Ineffective — 16 reports (10.06%) Headache — 15 reports (9.43%) Somnolence — 15 reports (9.43%) Death — 14 reports (8.81%) Rash — 14 reports (8.81%) Depression — 13 reports (8.18%) Vomiting — 13 reports (8.18%)
Source database →
Gabapentin 300mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Gabapentin 300mg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Gabapentin 300mg in United States?
British Columbia Cancer Agency is the originator. The local marketing authorisation holder may differ — check the official source linked above.